Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with t… Read more
Biofrontera Inc (BFRI) - Total Liabilities
Latest total liabilities as of September 2025: $18.00 Million USD
Based on the latest financial reports, Biofrontera Inc (BFRI) has total liabilities worth $18.00 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biofrontera Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Biofrontera Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biofrontera Inc Competitors by Total Liabilities
The table below lists competitors of Biofrontera Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Scientific Energy Inc
PINK:SCGY
|
USA | $28.81 Million |
|
PT Era Digital Media Tbk
JK:AWAN
|
Indonesia | Rp22.35 Billion |
|
Intermedical Care and Lab Hospital Public Company Limited
BK:IMH
|
Thailand | ฿1.22 Billion |
|
PT Royaltama Mulia Kontraktorindo Tbk
JK:RMKO
|
Indonesia | Rp418.30 Billion |
|
Xplus SA
WAR:XPL
|
Poland | zł19.44 Million |
|
Seung Il Corporation
KQ:049830
|
Korea | ₩26.20 Billion |
|
Khadim India Limited
NSE:KHADIM
|
India | ₹4.10 Billion |
|
240600
KQ:240600
|
Korea | ₩22.84 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Biofrontera Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biofrontera Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biofrontera Inc (2019–2024)
The table below shows the annual total liabilities of Biofrontera Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $17.67 Million | -23.64% |
| 2023-12-31 | $23.14 Million | -14.32% |
| 2022-12-31 | $27.01 Million | -35.52% |
| 2021-12-31 | $41.88 Million | +128.73% |
| 2020-12-31 | $18.31 Million | -68.93% |
| 2019-12-31 | $58.93 Million | -- |